Glocentrica Ltd is a UK biotechnology company dedicated to discovering, developing and commercializing innovative technologies that improve metabolic health, healthy ageing and precision nutrition.
Built on decades of internationally recognised research into the glyoxalase system, dicarbonyl stress and metabolic dysfunction, Glocentrica develops proprietary technologies that translate cutting-edge science into clinically validated health solutions. Our lead innovation, GlucoRegulate, is a patented nutritional formulation combining trans-resveratrol and hesperetin, supported by published clinical studies demonstrating improvements in insulin sensitivity and other markers of metabolic health.
In addition to technology development, Glocentrica provides scientific consultancy, translational research and strategic partnering to organizations developing next-generation products in metabolic health, obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), longevity and healthy ageing.
Our expertise spans molecular mechanisms, biomarker discovery, pre-clinical and clinical research, intellectual property development and product commercialization, enabling us to bridge world-class science with real-world healthcare innovation.
Glocentrica is actively seeking strategic partnerships, licensing opportunities, research collaborations and investment to accelerate the global development and commercialization of its patented technologies.
We welcome discussions with companies, investors and research organizations seeking differentiated, evidence-based innovations in metabolic health, longevity and precision nutrition.

Glocentrica

Org chart

Teams

Offices

Glocentrica

Org chart

Teams

Offices

Related companies